Fundraising FoxColumbus Venture Partners — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.
AI & Machine LearningBiotech
PartnerJose Mesa· solo GP
Co-investorsEpidarex CapitalPfizer Venture InvestmentsAdvent Life SciencesBritish Patient CapitalPfizer Ventures
Tolerance is a compliance platform that runs continuous automated checks against the NIST 800-171 standard and collects assessor-ready evidence for teams handling Controlled Unclassified Information (CUI).
CybersecurityGovTechSaaS
Co-investorsDorm RoomAmadeus Capital PartnersBen Franklin Technology PartnersBioAdvanceCriteria Bio VenturesEast Innovate+5 more
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.
BiotechDeep TechLongevityPhiladelphia, US
Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsBioAdvanceCriteria Bio VenturesBen Franklin Technology PartnersCaixa Capital Risc
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.